Introduction
============

T cells are critical for vertebrate adaptive immune responses, during which they function as both regulators and effectors of these processes ([@B25]). Abnormalities in T cells have frequently been reported in autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS), which is characterized by exaggerated activation of CD4^+^ T cells ([@B14]; [@B32]). Thus, it is essential to explore the pathogenesis of abnormally activated T cells in autoimmune diseases for the discovery of new drugs. Immunoglobulin D (IgD) includes membrane IgD (mIgD) and secreted IgD (sIgD), which remains a rather enigmatic player in the immune system. Reports have shown that sIgD might be increased in patients with autoimmune diseases ([@B19]) such as RA and SLE, consistent with our finding of elevated sIgD in RA ([@B38]). In addition, the IgD receptor (IgDR), which is expressed on T cells, can bind to sIgD to activate downstream signal transduction. Our previous study determined that excessive IgD can result in hyperactive CD4^+^ T cells, mediated by IgDR, which might indicate a common pathogenic mechanism of RA ([@B38]). Nguyen reported that the administration of anti-IgD can significantly attenuate the progression of experimental arthritis, indicating that IgD participates in CD4^+^ T cell-mediated autoimmune arthritis ([@B24]). These studies suggest that IgD plays a crucial part in the pathology of autoimmune diseases, which might be related to the exaggerated activation of CD4^+^ T cells. Rodent studies showed that the inhibition of protein tyrosine kinases (PTKs) can block the upregulation of IgD-induced IgDR, which was shown to involve Lck, Fyn, ZAP-70, and PLC-γ, among others ([@B20]). However, few studies have been performed to explore the function of IgD in human T cells.

Recently, our group has identified a new active monomer, paeoniflorin-6′-*O*-benzene sulfonate (code: CP-25; formula: C29H32O13S; molecular weight: 620; patent number in China: ZL201210030616.4) through the structural modification of paeoniflorin (Pae) ([@B34]; [@B41]). **Figure [1](#F1){ref-type="fig"}** shows the chemical construction of CP-25. We reported previously that CP-25 has therapeutic effects on rats with adjuvant-induced arthritis ([@B5]). We also found that CP-25 could regulate dendritic cell (DC) function and inhibit DC maturation *in vitro* ([@B22]). It can also attenuate the inflammatory response of BAFF-activated CD4^+^ T cells ([@B15]).

![Chemical structures of CP-25 (formula: C29H32O13S; molecular weight: 620).](fphar-09-00004-g001){#F1}

Since CD4^+^ T cell homeostasis is disturbed in autoimmune diseases and IgD is a critical mediator of homeostasis, we hypothesized that CP-25 could rebalance this CD4^+^ T cell homeostasis. We observed that blood levels of IgD were abnormally high in mice with collagen-induced arthritis (data not shown). Here, to simulate the blood environment of RA, we use IgD to stimulate T cells. Therefore, this study aimed to explore the role of IgD in CD4^+^ T cell activation and determine if CP-25 could regulate this process.

We first demonstrated that IgD activates human T cells through IgDR and Lck tyrosine (Tyr^394^) phosphorylation. These data are also the first to demonstrate that CP-25 can inhibit the activation and proliferation of CD4^+^ T cells stimulated by IgD, as well as the production of inflammatory cytokines. We further suggest that this process is probably related to the downregulation of Lck phosphorylation. The results highlight the potential of CP-25 as an ideal and new therapeutic agent for human autoimmune diseases.

Materials and Methods {#s1}
=====================

Reagents and Drugs
------------------

Human IgD was purchased from Abcam (Cambridge, MA, United States). CP-25 was provided by the Chemistry Lab of the Institute of Clinical Pharmacology of Anhui Medical University with a purity of 98.8% (Hefei, China). CP-25 was dissolved in DMEM. Herbimycin A (HA) was purchased from Millipore (Temecula, CA, United States). A770041 was purchased from Axon Medchem (Groningen, Netherlands). Biotinylated IgD was prepared in our laboratory using a protein biotinylation kit from Pierce Biotechnology (Rockford, IL, United States) according to the manufacturer's instructions. Human CD4 microbeads were purchased from Miltenyi Biotec (Germany). PE-anti-CD69, PE-anti-CD154, PE-anti-CD62L, PE-anti-IgD, PE-cy5-anti-CD4 monoclonal antibodies (mAbs), APC-Cy7-streptavidin and isotype-matched PE-labeled mouse IgG2a mAbs were purchased from BD Pharmingen (San Diego, CA, United States). The anti-Lck antibody was purchased from Cell Signaling Technology (Danvers, MA, United States).

Samples
-------

Peripheral blood samples from healthy volunteers, from the First Affiliated Hospital Medical Center, Anhui Medical University, were collected. This study was performed in accordance with the recommendations of the Declaration of Helsinki (2008) and the Ethics Review Committee for the Experimentation of the Institute of Clinical Pharmacology, Anhui Medical University; written informed consent was obtained from all subjects, in accordance with the Declaration of Helsinki. The protocol was approved by the Ethics Review Committee for the Experimentation of the Institute of Clinical Pharmacology, Anhui Medical University (No. 20140192).

CD4^+^ T Cells Magnetic Separation
----------------------------------

Peripheral blood mononuclear cells (PBMCs) were separated by density gradient centrifugation, and CD4^+^ T cells were isolated using magnetic cell separation through positive selection (Miltenyi Biotec, Germany). Labeled T cells were collected after washing with degassed buffer three times. Purity was verified by flow cytometry using PE-cy5 anti-CD4 mAbs. Staining with PE-cy5 anti-CD4 mAb established that isolated CD4^+^ T cells were 96% pure (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}), and staining with trypan blue indicated that they were 98% viable.

T Cell Viability and Proliferation Assay
----------------------------------------

CD4^+^ T cells were added to 96-well microtiter plates at 2 × 10^5^ cells/well in DMEM with 5% fetal bovine serum (FBS). T cells were cultured in the presence of 3 μg/ml IgD, and incubated for 24 h with the inhibitors HA (1 μmol/l), A770041 (0.5 μmol/l), or CP-25 (10^-7^, 10^-6^, and 10^-5^ mol/l) at 37°C, with 5% CO~2~. For each experiment, the vehicle control group (control) comprised CD4^+^ T cells treated with DMEM and 5% FBS only. T cell viability was assessed using the Cell Counting Kit-8 (WST-8; Dojindo Laboratories, Kumamoto, Japan), and a microplate reader (BioTek Elx-808) was used according to the manufacturer's protocol. T cell proliferation was assessed using the CFSE Cell Proliferation Kit (BestBio, Shanghai, China) following the protocol of the manufacturer. The working range of CFSE was 0.5--25 μmol/l; however, 4 μmol/l CFSE/10^7^ cells was satisfactory and avoided the toxicity that occasionally occurs with high concentrations of DMSO (used as the solvent for CFSE). After labeling, data were acquired using a flow cytometer (model FC 500; Beckman Coulter Ltd., United States) and data were analyzed with CXP analysis software (Beckman Coulter Ltd., United States, version 2.0).

Fluorescence-Based Receptor Binding Assay and Scatchard Analysis
----------------------------------------------------------------

The intrinsic binding affinity between the fluorescence-labeled IgD antibody and IgD on IgDR in CD4^+^ T cells was evaluated by fluorescence-based receptor binding assays ([@B37]; [@B23]). IgD binding for detection by flow cytometry was performed as follows. Various concentrations of IgD (0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, and 30 μg/ml) were used. Maximal binding of IgD was observed using CD4^+^ T cells in six-well microtiter plates at 1 × 10^6^ cells/well, incubated at 37°C for 2 h in fresh medium (with 0.1% BSA). Cells were then washed three times with PBS at room temperature (RT), and then with buffer appropriate for the assay. IgD binding was detected with a PE-anti-IgD antibody, and isotype-matched PE-labeled mouse IgG2a mAbs were used to assess non-specific binding. The binding of IgD to the anti-IgD antibody was analyzed by flow cytometry. To measure the affinity of the fluorescent IgD ligand, the intensity values corresponding to the maximum fluorescence emission were plotted against total ligand concentrations. Ligand binding properties were evaluated by the fluorescence intensities, assuming that the protein was 100% active, with a stoichiometry of 1:1 (protein:ligand) at saturation. The curves were made linear using Scatchard Plots. The *K*~D~ values for IgD protein were then calculated ([@B39]).

Flow Cytometric Analysis
------------------------

Surface markers of CD4^+^ T cells were evaluated by flow cytometry. CD4^+^ T cells were incubated with PE-anti-CD69 and PE-anti-CD154 mAbs or isotype-matched PE-labeled mouse IgG2a mAbs for 30 min at RT. To determine the expression of IgDR in T cell subsets, human PBMCs were treated with different concentration of IgD and/or CP-25 for 24 h. After incubation, the expression of IgDR was detected using biotinylated IgD followed by APC-Cy7-conjugated streptavidin ([@B9]; [@B38]). Cells stained with APC-Cy7 conjugated streptavidin alone were used as an isotype control. After labeling, data were acquired using a flow cytometer and data were analyzed with CXP analysis software. For analysis, the lymphocyte population was gated based on forward and side scatter. Total T cells (CD3^+^), helper T cells (CD3^+^CD4^+^), unactivated T cells (CD4^+^CD62L^+^), and activated T cells (CD4^+^CD69^+^, CD4^+^CD154^+^) were gated. The expression of IgDR on T cells was analyzed by calculating the percentages of CD3^+^IgDR^+^, CD3^+^CD4^+^IgDR^+^, CD4^+^CD62L^+^IgDR^+^, CD4^+^CD69^+^IgDR^+^, and CD4^+^CD154^+^IgDR^+^.

Western Blotting
----------------

CD4^+^ T cells were added to six-well microtiter plates at 5 × 10^6^ cells/well, and treated with different concentrations of IgD and/or CP-25 for 24 h at 37°C and 5% CO~2~. After culture, cells were lysed and centrifuged at 2000 ×*g* for 20 min at 4°C. The supernatants of cultures were collected and maintained at -80°C until use. Protein samples were fractionated by 10% SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride microporous membranes (Bio-Rad, Shanghai, China). After blocking with blocking buffer (0.05% Tween 20-PBS with 5% non-fat milk) for 37°C for 2 h, biotinylated IgD was used as the primary antibody for IgDR, overnight at 4°C. Subsequently, cells were treated with HRP-conjugated streptavidin as the secondary antibody (Beyotime Institute of Biotechnology) at 37°C for 2 h. Immunodetection was performed using enhanced chemiluminescence reagent according to the manufacturer's instructions. Equivalent protein loading and transfer efficiency were verified by β-actin staining. The GSM-3.0 gel graph analyzing system was used to calculate the densitometry of each band.

Cytokine Assays
---------------

The secretion of different cytokines from cultured CD4^+^ T cells was measured by using the Quantibody Human Inflammation Array 1 from Ray Biotech (Norcross, GA, United States). In brief, antibodies against different cytokine \[IL-1α, IL-1β, TNF-α, IL-6, IL-10, IL-8, IL-4, INF-γ, IL-13, and monocyte chemotactic protein (MCP)-1\] were spotted onto the cytokine array by the manufacturer. CD4^+^ T cells were treated with different concentrations of IgD and/or CP-25 for 24 h in 24-well plates, and incubated at 37°C, 5% CO~2~. Secreted cytokine quantities were measured by adding 100 μl of conditioned medium onto the array for 2 h. Following stringent washes with supplied buffers, detection antibody was added to each well for 1 h at RT and Cy3-equivalent dye-conjugated streptavidin was added for another 1 h at RT to detect bound cytokine. The signal intensity for each spot was determined using an Axon GenePix laser scanner (GenePix 4000B; Molecular Devices, United States) equipped with Cy3 wavelength detection (555 nm excitation, 565 nm emission). The image was analyzed using GenePix Pro 7.0 software, and cytokines were quantified according to the standard curve calibrated from the same array. Outliers were removed and standard curves were then created. Both linear and log regression curves were generated and the curve that gave the best regression line (*r*^2^ closest to 1), was used to determine sample concentrations.

Statistical Analyses
--------------------

Statistical analysis was performed by analysis of variance (ANOVA) using SPSS 11.5 software (SPSS, Inc., Chicago, IL, United States). ANOVA was used exclusively for multi group comparisons. Parametric or non-parametric tests were used based on the normality of distribution. Data were presented as the mean ± standard error of the mean unless otherwise indicated. Differences with *P*-values less than 0.05 were considered statistically significant.

Results
=======

Binding Affinity between IgD and IgDR
-------------------------------------

To determine whether the observed binding of IgD to IgDR on CD4^+^ T cells occurred with the characteristics of receptor--ligand interaction, experiments were designed to demonstrate receptor saturation and binding affinity. CD4^+^ T cells were separated from healthy donors using magnetic beads. The affinity of human IgD was detected using a PE-conjugated anti-IgD antibody. Binding of IgD to IgDR, expressed on T cells, was also determined using IgD as the ligand. Binding between IgD and IgDR was clearly concentration-dependent (**Figure [2A](#F2){ref-type="fig"}**). We estimated the IgD binding affinity by performing a fluorescence-based receptor binding assay. Total, non-specific, and specific binding vs. IgD concentrations were plotted as shown in **Figure [2A](#F2){ref-type="fig"}**. The Scatchard line transformed from the specific binding data was plotted as shown in **Figure [2B](#F2){ref-type="fig"}**. The *B*~max~ and *K*~D~ values were calculated by Scatchard plot analysis. The *K*~D~ value was 2.16 × 10^-10^ mol/l, which represents high-affinity, and the *B*~max~ value was 5470 arbitrary units/10^4^ cells (**Figure [2B](#F2){ref-type="fig"}**).

![Ligand binding assays on CD4^+^ T cells. Human CD4^+^ T cells expressing immunoglobulin D receptor (IgDR) were incubated with human immunoglobulin D (IgD) for 2 h at 37°C and washed three times. Cells with bound fluorescent ligands were determined by flow cytometry. Cells (1 × 10^4^) were collected for each sample and the ligand binding properties were evaluated by assessing the fluorescence intensities of 1 × 10^4^ cells. IgD binding was detected with PE-anti-IgD antibody, and isotype-matched PE-labeled mouse IgG2a monoclonal antibodies (mAbs) were used to calculate non-specific binding. Values for non-specific binding, determined using the isotype control, were subtracted. Data are plotted as Scatchard analyses and are representative of several independent experiments, *n* = 5. **(A)** Total, non-specific, and specific binding vs. IgD concentrations were plotted. **(B)** The Scatchard line was transformed from the specific binding values. *B*~max~ and *K*~D~ values were calculated by Scatchard plot analysis.](fphar-09-00004-g002){#F2}

Effect of IgD on T Cell Proliferation and Activation
----------------------------------------------------

To determine if IgD activates CD4^+^ T cells via PTK signaling pathways and the phosphorylation of Lck, we used the PTK inhibitor HA and the Lck inhibitor A770041. Subsequently, we first investigated the effects of IgD on T cell proliferation. T cells were incubated for 18 h with HA and for 24 h with A770041 separately before culturing in the presence of 3 μg/ml IgD. As shown in **Figure [3A](#F3){ref-type="fig"}**, IgD (3 μg/ml) significantly promoted the proliferation of CD4^+^ T cells, whereas HA (1 μmol/l) or A770041 (0.5 μmol/l) treatment markedly inhibited IgD-induced proliferation. Next, the expression of CD69 and CD154 on T cells treated with IgD for 24 h was analyzed by flow cytometry (**Figures [3B,C](#F3){ref-type="fig"}**). Significant increases in the proportions of CD69^+^ and CD154^+^ subsets in CD4^+^ T cell populations were caused by IgD (3 μg/ml), whereas A770041(0.5 μmol/l) significantly suppressed this effect.

![Effect of protein tyrosine kinase (PTK) inhibitors on the stimulatory effect of immunoglobulin D (IgD) in CD4^+^ T cells. Human CD4^+^ T cells were cultured with IgD (3 μg/ml) and inhibitors herbimycin A (HA; 1 μmol/l) or A770041 (0.5 μmol/l) for 24 h. Trypan blue-labeled CD4^+^ T cells in each group indicated that cells were 98% viable. **(A)** Proliferation of CD4^+^ T cells, as detected by CCK-8. Flow cytometry was used to analyze the proportions of CD69^+^ **(B)** and CD154^+^ **(C)** in CD4^+^ T cell populations. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. control; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. IgD (3 μg/ml) group.](fphar-09-00004-g003){#F3}

IgD Upregulates IgDR Expression and Lck Phosphorylation in CD4^+^ T Cells
-------------------------------------------------------------------------

As the amount of IgDR on activated T cells was enhanced by IgD, we further examined whether this treatment could enhance the expression of IgDR itself in CD4^+^ T cells by performing western blots. CD4^+^ T cells were stimulated by IgD (3 μg/ml) for 0.5, 2, 4, 6, 12, and 24 h. As expected, the protein expression of IgDR (approximately 70 kDa) increased after a 12 h-co-culture with IgD. For the next experiment, we chose 24 h as an optimal time for stimulation (**Figure [4A](#F4){ref-type="fig"}**). Furthermore, the expression of IgDR was increased in response to treatment with IgD in a concentration-dependent manner (**Figure [4B](#F4){ref-type="fig"}**, *P* \< 0.05). The expression could also be increased by treatment with phytohemagglutinin (PHA, 4 μg/ml; Sigma, St. Louis, MO, United States). Lck is critically involved in the initial phase of T cell signal transduction. We thus examined whether treating CD4^+^ T cells with IgD could result in activation of Lck (Tyr^394^) tyrosine phosphorylation. As shown in **Figure [4C](#F4){ref-type="fig"}**, sIgD stimulation resulted in enhanced Lck phosphorylation compared to that in the medium control sample. The expression of Lck was not changed. We used the inhibitor HA and Lck to separately investigate the effects IgD on inhibition of PTK signaling and Lck phosphorylation. For inhibition experiments, T cells were incubated for 18 h with HA and for 24 h with A770041 separately before administering 3 μg/ml IgD. As shown in **Figures [4D,E](#F4){ref-type="fig"}**, HA (1, 2, and 4 μmol/l) or A770041 (0.15, 0.45, and 1.35 μmol/l) inhibited IgD-induced Lck phosphorylation.

![Effect of immunoglobulin D (IgD) and inhibitors on the expression of immunoglobulin D receptor (IgDR), Lck, and P-Lck in human CD4^+^ T cells. Data are expressed as the mean ± standard error of the mean (*n* = 3). **(A)** Western blot analysis of IgDR expression in CD4^+^ T cells stimulated with IgD at different times (0--24 h); ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. 0 h. Western blot analysis of IgDR **(B)**, Lck **(C)**, and P-Lck **(C)** expression in CD4^+^ T cells stimulated with IgD at different concentrations (1∼10 μg/ml); ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.05 vs. control. Western blot analysis of Lck and P-Lck expression in CD4^+^ T cells stimulated with IgD (3 μg/ml) after pretreatment with herbimycin A **(D)** and A770041 **(E)**; ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. control, ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. IgD (3 μg/ml) group.](fphar-09-00004-g004){#F4}

CP-25 Inhibits IgD-Induced PBMC and CD4^+^ T Cell Proliferation
---------------------------------------------------------------

PBMCs were cultured with different concentrations of CP-25 (10^-9^∼10^-5^ mol/l) combined with IgD (3 μg/ml) for 24, 48, and 72 h. IgD significantly promoted proliferation in PBMCs, whereas CP-25 (10^-7^∼10^-5^ mol/l) treatment markedly inhibited IgD-induced proliferation after 24 h of culture (**Figure [5A](#F5){ref-type="fig"}**, *P* \< 0.05). As such, CP-25 had no significant effect on PBMC proliferation (data not shown). Next, we investigated the effect of CP-25 on IgD-induced CD4^+^ T cell proliferation. Of note, CP-25 (10^-7^∼10^-5^ mol/l) treatment markedly inhibited IgD-induced proliferation after 24 h of culture (**Figure [5B](#F5){ref-type="fig"}**, *P* \< 0.01). CFSE dye irreversibly binds cytoplasmic proteins and is evenly distributed between daughter cells during cell division. Flow cytometry revealed a cell population with lower fluorescence intensity compared to that in initial cells (**Figure [5C](#F5){ref-type="fig"}**). Consistently, IgD (3 μg/ml) stimulated the proliferation of CD4^+^ T cells, as compared to that in the control group. The suppression of proliferation was pronounced after CP-25 (10^-7^∼10^-5^ mol/l) treatment, as characterized by a deceleration of cell division.

![Effect of CP-25 on proliferation of human peripheral blood mononuclear cells (PBMCs) and CD4^+^ T cells stimulated with immunoglobulin D (IgD) *in vitro.* CD4^+^ T cells in each group were 98% viable, based on trypan blue staining. PBMCs were cultured with different concentrations of CP-25 (10^-9^∼10^-5^ mol/l) combined with IgD (3 μg/ml) for 24, 48, and 72 h, and the viability of PBMCs was detected by CCK-8 **(A)**. Purified CD4^+^ T cells were cultured with IgD alone or CP-25 in addition. The viability and proliferation of T cells were separately detected by CCK-8 **(B)** and CFSE analysis **(C)**. Data are expressed as the mean ± standard error of the mean (*n* = 3). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. control; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. IgD (3 μg/ml) group.](fphar-09-00004-g005){#F5}

CP-25 Suppresses IgD-Enhanced T Cell Subset Activation
------------------------------------------------------

Next, the effects of CP-25 on T cell activation were analyzed (**Figure [6](#F6){ref-type="fig"}**). Results showed that the proportions of activated T cells (CD4^+^CD69^+^, CD4^+^CD154^+^; *P* \< 0.05) increased after co-culturing with IgD (3 μg/ml) for 24 h. IgD had no significant effect on total helper T cells (CD3^+^CD4^+^) or unactivated T cells (CD4^+^CD62L^+^). CP-25 (10^-7^∼10^-5^ mol/l) significantly decreased the proportion of CD4^+^CD154^+^ induced by IgD (**Figure [6B](#F6){ref-type="fig"}**, *P* \< 0.05). CP-25 (10^-5^ mol/l) significantly decreased the proportion of CD4^+^CD69^+^ cells induced by IgD (**Figure [6C](#F6){ref-type="fig"}**, *P* \< 0.05). Accordingly, CP-25 had no significant effect on each T cell subset (Supplementary Figure [2](#SM1){ref-type="supplementary-material"}).

![Effect of CP-25 on the proportions of T cell subsets and the expression of immunoglobulin D receptor (IgDR) in human peripheral blood mononuclear cells (PBMCs) induced by immunoglobulin D (IgD). Human PBMCs were cultured with different concentrations of CP-25 (10^-9^∼10^-5^ mol/l) combined with IgD (3 μg/ml) for 24 h. Flow cytometry was used to analyze the effects of CP-25. After incubation, the expression of IgDR was detected using biotinylated IgD followed by APC-Cy7-conjugated streptavidin. Cells stained with APC-Cy7 conjugated streptavidin alone were used as an isotype control. **(A)** Representative flow cytometry dot plot from each group. Bar graph illustrating the proportion of CD4^+^/CD154^+^ **(B)**, CD4^+^/CD69^+^ **(C)**, CD4^+^/CD62L^+^ **(D)**, CD3^+^/IgDR^+^ **(E)**, CD3^+^/CD4^+^/IgDR^+^ **(F)**, and CD4^+^/CD154^+^/IgDR^+^ **(G)** T cells. Data are expressed as the mean ± standard error of the mean (*n* = 5). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. control group; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. IgD group.](fphar-09-00004-g006){#F6}

CP-25 Decreases the IgD-Mediated Expression of IgDR in T Cell Subsets
---------------------------------------------------------------------

The expression of IgDR on T cell subsets was analyzed after treatment with different concentrations of IgD and/or CP-25 for 24 h. A significant increase in the proportions of CD3^+^IgDR^+^, CD3^+^CD4^+^IgDR^+^, and CD4^+^ CD154^+^IgDR^+^ T cells was observed with IgD (3 μg/ml; **Figure [6](#F6){ref-type="fig"}**, *P* \< 0.05) in PBMC. IgD had no significant effect on the proportions of CD4^+^CD62L^+^IgDR^+^ T cells. CP-25 (10^-7^∼10^-5^ mol/l) significantly decreased the proportion of CD3^+^IgDR^+^ and CD4^+^CD154^+^IgDR^+^ T cells induced by IgD after 24 h of culture (**Figures [6E,G](#F6){ref-type="fig"}**, *P* \< 0.05). Further, CP-25 (10^-6^∼10^-5^ mol/l) significantly decreased the percentage of CD3^+^CD4^+^IgDR^+^ T cells induced by IgD (3 μg/ml) after 24 h of culture (**Figure [6F](#F6){ref-type="fig"}**, *P* \< 0.05). The percentage of CD4^+^CD69^+^IgDR^+^ T cells was too low to be detected.

CP-25 Decreases the Production of Inflammatory Cytokines Secreted by IgD-Activated T Cells
------------------------------------------------------------------------------------------

To examine whether CP-25 affects inflammatory cytokine secretion by IgD-activated T cells, inflammatory cytokines were analyzed by the Quantibody Human Inflammation Array. Compared to those in the control group, the concentrations of IL-1α, IL-1β, IL-6, IL-8, and TNF-α were increased significantly with the treatment of IgD (3 μg/ml; *P* \< 0.05; **Figure [7](#F7){ref-type="fig"}**). There were no obvious differences in the concentrations of IL-10, IL-4, INF-γ, IL-13, and MCP-1. As shown in **Figure [7](#F7){ref-type="fig"}**, CP-25 (10^-5^ mol/l) significantly decreased the production of IL-1α, IL-1β, IL-6 induced by IgD after 24 h of culture; moreover, CP-25 (10^-6^∼10^-5^ mol/l) decreased the production of TNF-α and CP-25 (10^-7^∼10^-5^ mol/l) decreased the production of IL-8.

![Variation in inflammatory cytokine secretion by human CD4^+^ T cells stimulated by immunoglobulin D (IgD) and the effect of CP-25. Cell culture supernatants were collected after treated with IgD (3 μg/ml) and CP-25 (10^-7^∼10^-5^ mol/l) for 24 h. The glass slide was scanned using a microarray scanner, and levels of IL-1α **(A)**, IL-1β **(B)**, IL-6 **(C)**, IL-8 **(D)**, and TNF-α **(E)** were measured. Data are expressed as the mean ± standard error of the mean (*n* = 4). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. control; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. IgD group.](fphar-09-00004-g007){#F7}

CP-25 Downregulates IgD-Induced IgDR Expression and Lck Phosphorylation
-----------------------------------------------------------------------

We found that CP-25 can inhibit the activation of CD4^+^ T cells induced by IgD, and further examined whether CP-25 could rebalance CD4^+^ T cell homeostasis by downregulating total IgDR protein expression and Lck phosphorylation (Tyr^394^). As expected, CP-25 (10^-7^∼10^-5^ mol/l) downregulated the total protein expression of IgDR (**Figure [8A](#F8){ref-type="fig"}**), and CP-25 (10^-5^ mol/l) significantly downregulated IgD-induced Lck phosphorylation to control levels (**Figure [8B](#F8){ref-type="fig"}**).

![Effects of CP-25 on the expression of immunoglobulin D receptor (IgDR) and Lck in human CD4^+^ T cells stimulated with immunoglobulin D (IgD). CD4^+^ cells were treated with IgD (3 μg/ml) and CP-25 (10^-7^∼10^-5^ mol/l) for 24 h and lysed. **(A)** Western blot analysis of IgDR expression in CD4^+^ T cells. **(B)** Western blot analysis of Lck and P-Lck expression in CD4^+^ T cells. Data are expressed as the mean ± standard error of the mean (*n* = 3). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. control; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. IgD (3 μg/ml) group.](fphar-09-00004-g008){#F8}

Discussion
==========

IgD plays a key role in innate immunity and inflammation ([@B6]). Whereas the function of IgM, IgG, IgA, and IgE is relatively well-known, the function of IgD has remained obscure for a significant amount of time. Low concentrations of IgD are secreted under physiological conditions ([@B27]; [@B33]), whereas increased IgD can occur in atypical situations such as IgD myeloma, skin allergy, hyper IgE and hyper IgD syndromes, and autoimmune disorders such as RA and SLE ([@B26]; [@B10]; [@B28]). However, high expression of sIgD was found to be associated with high levels of protein-like sediments and cell necrosis in the kidney, spleen, and liver of transgenic mice ([@B35]); further, recent studies have suggested that IgD might play an important role in autoimmune diseases. The function of IgD has remained elusive since its discovery, despite numerous attempts to define its biological purpose. Surprisingly, the existence of an Fc receptor specific for IgD (FcR or IgDR) is still not entirely clear. Its existence on T cells has been suggested ([@B8]). *In vivo* and *in vitro* studies have suggested that a putative IgDR on T cells might play a role in the regulation of IgD ([@B10]; [@B20]; [@B28]). Recently, our group reported further evidence for the existence of an IgDR on B cells ([@B38]), the human Burkitt lymphoma B cell line Daudi ([@B9]), and human fibroblast-like synoviocytes (FLSs; [@B39]).

T cell activation usually occurs with increased expression of CD69 and CD154 (CD40L) ([@B4]). We reported that the proportions of activated T cells (CD4^+^CD69^+^, CD4^+^CD154^+^) increases after co-culture with IgD both in RA patients and in healthy controls. In particular, IgD was shown to induce a rapid increase in CD4^+^IgDR^+^ T cells in RA patients ([@B38]). CD4^+^ T cells, which are critical elements of vertebrate adaptive immune responses, are produced in the thymus and migrate to the periphery where they encounter antigens. Whereas aberrant control of Th immune response is implicated in the progression of autoimmune diseases such as RA, SLE, ulcerative colitis ([@B40]; [@B13]). Our group has proposed that CD4^+^ T cells might be key effectors in RA patients. Excessive IgD probably causes the activation of CD4^+^ T cells, resulting in the abnormal proliferation of PBMCs and increased secretion of inflammatory cytokines.

To clearly illustrate the mechanism associated with IgD on CD4^+^ T cells, we determined the effect of IgD on CD4^+^ T cells isolated from humans. We found that IgD binds IgDR on T cells with high affinity. A significant increase in the proportion of CD69^+^ and CD154^+^ cells in CD4^+^ T populations was caused by IgD. Simultaneously, the expression of IgDR on activated T cells (CD4^+^/CD154^+^) was elevated after IgD stimulation. Our data suggested that IgD promotes the activation of T cells by stimulating the expression of IgDR. In this study, IgD significantly enhanced the proliferation of CD4^+^ T cells and increased levels of inflammatory cytokines including IL-α, IL-1β, IL-6, IL-8, and TNF-α secreted by CD4^+^ T cells, which was consistent with previous reports on PBMCs from RA patients ([@B7]; [@B38]). IL-1, IL-6, and TNF-α are key inflammatory cytokines that play a critical role in T cell activation, tissue destruction, and joint inflammation in RA ([@B18]; [@B16]). Our results demonstrated that IL-1, IL-6, and TNF-α are released from activated T cells; in addition, to date, IgD has been considered an important participant in the pathophysiology of RA.

Further, functional analysis of IgDR and its signaling pathway were performed in this study to provide a clearer explanation of the molecular mechanisms that regulate T cell activation. Reports focusing on IgDR-related signaling were previously limited. In mice, crosslinking of IgDR might induce signal transduction through the activation of PTK pathways ([@B1]); total protein expression of IgDR and phosphorylation of Lck were previously shown to be enhanced by IgD in mouse T cells ([@B20]). Furthermore, the tyrosine kinase Lck plays a crucial role in the maturation of lymphocytes in the thymus and in mature T cell activation and proliferation ([@B12]; [@B2]; [@B17]; [@B31]). Lck hyperactivation leads to an overall enhanced TCR downstream signaling, including JNK activation TCR signaling ([@B21]). Dysregulation of the expression and activity of Lck was described in lymphocytes from SLE patients ([@B2]). Inhibitors of Lck are suggested to be efficacious for the treatment of inflammatory-immune diseases including RA, MS, inflammatory bowel diseases, type 1 diabetes, SLE, and psoriasis ([@B29]). In this study, we found that the total protein expression of IgDR and the activation of Lck (Tyr^394^) tyrosine phosphorylation were enhanced by IgD in CD4^+^ T cells. However, the expression of Lck was not changed. A previous study showed that HA, which is a tyrosine kinase inhibitor, can block PTK signaling and significantly inhibit the induction of IgDR in murine cells ([@B1]; [@B30]). We used the inhibitors HA and A770041 to confirm whether Lck is the key molecular mediator of IgD-induced T cell activation. A770041 is a selective inhibitor of Lck ([@B29]; [@B3]; [@B11]). Both HA and A770041 could significantly inhibit the phosphorylation of Lck after IgD stimulation. Compared to that in the control, the activating effect on proliferation caused by IgD was blocked by HA or A770041 in CD4^+^ T cells. A770041 could significantly attenuate the IgD-induced proportion of CD69^+^ and CD154^+^ cells in CD4^+^ T cells. This finding might demonstrate that IgD can upregulate the expression of IgDR, activate CD4^+^ T cells, and promote the proliferation and secretion of inflammatory cytokines in CD4^+^ T cells by enhancing the phosphorylation of Lck (Tyr^394^). Our results support the hypothesis that IgD plays an important role in the activation of T cells in pathogenesis of RA.

CP-25, a novel ester derivative of Pae, was synthetized by our group. The protective effects of this compound during adjuvant-induced arthritis have been reported recently ([@B5]). *In vitro* studies have illustrated that CP-25 inhibits the growth and cytokine secretion ability of FLSs in a rat model of RA ([@B15]). Its therapeutic effect was related to the regulation of T/B cells and FLSs. Thus, we assume that CP-25 can suppress the abnormal activation of T cells induced by IgD, and that the mechanism through which CP-25 inhibits the activation of T cells is related to the expression of IgDR and Lck.

In this study, data showed that CP-25 significantly decreases proliferation and inflammatory cytokine secretion in IgD-induced CD4^+^ T cells *in vitro*. CP-25 reduced the secretion of cytokines to a similar level to that observed in the unstimulated group. Flow cytometry results showed that CP-25 decreases the proportion of IgD-induced activated T cells (CD4^+^/CD154^+^, CD4^+^/CD69^+^). Simultaneously, CP-25 could also reduce the expression of IgDR on activated T cells (CD4^+^/CD154^+^), of which the level was otherwise increased due to IgD, whereas CP-25 had no significant effect on total and immature T cells. Moreover, CP-25 could significantly decrease the IgD-induced expression of IgDR and the phosphorylation of Lck in CD4^+^ T cells. We observed that the level of IgD in blood was abnormally high in mice with collagen-induced arthritis (data not shown). Here, we used IgD to stimulate T cells to simulate the blood environment of RA patients. These results indicated that IgD promotes the activation of CD4^+^ T cells, and that CP-25 could selectively act on active T cells, decreasing the levels of active T cells to control levels, by regulating the phosphorylation of Lck. We observed that CP-25 could cross the cell membrane into the cytoplasm (data not shown). As such, one possible mechanism for this is that CP-25 inhibits the phosphorylation of Lck, inhibits the activation of T cells, down regulates the expression of IgDR, and then decreases the binding of IgD to the overexpressed IgDR. This mechanism might be related to the "soft regulation of inflammatory immune responses (SRIIR)" overexpressing IgDR on T cells. SRIIR, which was proposed by our group recently ([@B36]), is a new concept for the discovery and development of new drugs for the treatment of inflammatory immune responses related diseases. It refers to drugs that do not completely suppress cell function, as well as gene and protein expression or activity, but regulate selectively abnormal activity to achieve physiological levels, restore dynamic balance, and play a role in the treatment and reduction of adverse reactions. SRIIR provides a crucial direction for the development of innovative drugs. Our results indicated that CP-25 probably is a SRIIR drug, which could mildly decrease the production of activated T cells and reduce the excessive secretion of inflammatory cytokines to physiological levels.

Taking these data together, our study showed that IgD takes part in activating CD4^+^ T cells via the IgDR--Lck axis, which was consistent with our idea that the abnormally high level of IgD released by B cells plays an important role in RA. CP-25 can inhibit the IgD-stimulated activation and proliferation of CD4^+^ T cells, as well as the production of inflammatory cytokines, and this process is probably related to the downregulation of Lck phosphorylation. The results highlight the potential for CP-25 to be a novel and ideal agent to treat RA and other autoimmune diseases.
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CP-25

:   paeoniflorin-6′-*O*-benzene sulfonate

FLSs

:   fibroblast-like synoviocytes

HA

:   herbimycin A

IgD

:   immunoglobulin D

IgDR

:   immunoglobulin D receptor

mIgD

:   membrane IgD

MS

:   multiple sclerosis

PBMC

:   peripheral blood mononuclear cell

PHA

:   phytohemagglutinin

PTK

:   protein tyrosine kinase

RA

:   rheumatoid arthritis

sIgD

:   secreted IgD

SLE

:   systemic lupus erythematosus

SRIIR

:   soft regulation of inflammatory immune responses

UC

:   ulcerative colitis
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